id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-270622-aofva2ab	Li, Qizhang	Potential clinical drugs as covalent inhibitors of the priming proteases of the spike protein of SARS-CoV-2	2020-08-26		.txt	text/plain	2830	165	55	title: Potential clinical drugs as covalent inhibitors of the priming proteases of the spike protein of SARS-CoV-2 Based on the "steric-clashes alleviating receptor (SCAR)" strategy developed in our lab recently, we screened the library of clinic and investigational drugs, and identified nine drugs that might be repurposed as covalent inhibitors of the priming proteases (cathepsin B, cathepsin L, and TMPRSS2) of the spike protein of SARS-CoV-2. After careful filtering and 79 evaluation, we identified five (trapoxin B, neratinib, HKI-357, domatinostat and (Z)-dacomitinib) 80 potential covalent inhibitors for CatB, three (neratinib, HKI-357 and (Z)-dacomitinib) for CatL Although the docked poses 160 were slightly different on these two proteins, the warheads of these drugs were also at the positions 161 suitable for covalent bonding (Figure 3F-H) Taken together, using our SCARdock protocol, we identified nine drugs that might be repurposed as 229 the covalent inhibitors of the priming proteases of the S protein of SARS-CoV-2.	./cache/cord-270622-aofva2ab.txt	./txt/cord-270622-aofva2ab.txt